Barclays upgraded Corteva (CTVA) to Overweight from Equal Weight with a price target of $84, up from $75. The firm sees the company benefitting from solid acreage growth in Latin America. Corteva’s cost savings and innovation are boosting its profitability, the analyst tells investors in a research note. Barclays sees 8% adjusted EBITDA growth in the second half of 2025 for Corteva along with double-digit gains in 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTVA: